Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib

A large number of EGFR mutant non‐small cell lung cancer patients primordially benefit from first‐line treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. However, multiple acquired resistance mechanisms have been described that limit the clinical...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Thorac Cancer
Main Authors: Tang, Kejing, Jiang, Neng, Kuang, Yukun, He, Qiong, Li, Shuhua, Luo, Jiping, Jiang, Wenting, Chen, Yangshan, Sun, Yu, Chen, Lili, Chen, Yanyang, Zhu, Junfeng, Cui, Yongmei, Wan, Han, Ke, Zunfu
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons Australia, Ltd 2018
Fag:
Case Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360229/
https://ncbi.nlm.nih.gov/pubmed/30521113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12927
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker